Market Cap (In USD)
59.08 Million
Revenue (In USD)
58.59 Million
Net Income (In USD)
483.48 Thousand
Avg. Volume
47.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 64.0-80.0
- PE
- -
- EPS
- -
- Beta Value
- -0.248
- ISIN
- US09065J1016
- CUSIP
- 09065J101
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Dr. Mark G. Lewis Ph.D.
- Employee Count
- -
- Website
- https://www.bioqual.com
- Ipo Date
- 2002-06-21
- Details
- Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
More Stocks
-
MMNNFMunters Group AB (publ)
MMNNF
-
BNDSFBanco de Sabadell, S.A.
BNDSF
-
ATX
-
300969NINGBO HENGSHUAI Co., LTD.
300969
-
FRASERFraser and Company Limited
FRASER
-
FRT
-
300414
-
605098